Drug interactions in dermatological practice

Clinical and Experimental Dermatology

Volumn 33, Issue 5, 2008, Pages 541-550

  Tey, H L ^a   Tian, E L ^a   Tan, A W ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ANTACID AGENT; ANTIINFECTIVE AGENT; CALCIUM; CARBAMAZEPINE; CYCLOSPORIN A; CYTOCHROME P450 3A4; DAPSONE; DIGOXIN; DILTIAZEM; ERGOT DERIVATIVE; ERYTHROMYCIN; FELODIPINE; IMMUNOSUPPRESSIVE AGENT; IRON; KETOCONAZOLE; MACROLIDE; MAGNESIUM; PHENYTOIN; PROTEINASE INHIBITOR; QUINOLONE; RETINOIC ACID; RETINOID; RIFAMPICIN; STATIN; SULFONAMIDE; TETRACYCLINE; THEOPHYLLINE; VERAPAMIL; WARFARIN;

ALOE VERA; ANGELICA SINENSIS; CHELATION; CLINICAL PRACTICE; CRANBERRY JUICE; DERMATOLOGY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; EVENING PRIMROSE; FOOD DRUG INTERACTION; GINKGO BILOBA; GRAPEFRUIT JUICE; HUMAN; HYPERICUM PERFORATUM; MILK; PHARMACODYNAMICS; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYPHARMACY; RISK FACTORS; SKIN DISEASES;

EID: 49649086702     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.02904.x     Document Type: Review

References (16)

1. Baxter K, ed. Stockley's Drug Interaction. London: RPS publishing, 2007.
2. Rupp MT, De Young M, Schondelmeyer SW. Prescribing problems and pharmacist interventions in community practice. Med Care 1992 30: 926 40.
3. Rotman BL, Sullivan AN, McDonald T et al. A randomized evaluation of a computer-based physician's workstation; design considerations and baseline results. Proc Annu Symp Comput Appl Med Care 1995 693 7.
4. Linnarsson R. Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system. Scand J Prim Health Care 1993 11: 181 6.
5. Stanton LA, Peterson GM, Rumble RH et al. Drug-related admissions to an Australian hospital. J Clin Pharm Ther 1994 19: 341 7.
6. 2006. The Critical Path Institute, Arizona Center for Education and Research on Therapeutics. http://www.torsades.org (accessed 9 June 2008
7. Kahn LH, Alderfer RJ, Graham DJ. Seizures reported with tramadol. JAMA 1997 278: 1661.
8. Medsafe: New Zealand Medicines and Medical Devices Safety Authority. http://www.medsafe.govt.nz (accessed 29 February, 2008).
9. American Society of Health-System Pharmacists. American Hospital Formulary Service Drug Information, 2006. Bethesda: ASHP, 2006 3605.
10. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007 56: 1433 9.
11. Advisory Committee on Immunization Practices. General Recommendations on Immunisation. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 55: 1 48.
12. Fosamax (alendronate sodium) US prescribing Information. Merck & Co., Inc. November, 2006.
13. Didronel (etidronate disodium) US prescribing Information. Proctor & Gamble Pharmaceuticals, Inc. May, 2005.
14. Skelid (tiludronate disodium) US prescribing information. Sanofi-Aventis U.S. LLC April, 2006.
15. Actonel (risedronate sodium) US prescribing Information. Procter & Gamble Pharmaceuticals, Inc. April, 2007.
16. Boniva (ibandronate sodium) US prescribing Information. Roche Laboratories Inc. August, 2006.